Glioblastomas are aggressive brain tumors with a median survival time of less than 22 months despite standard therapy including surgery, irradiation, and chemotherapy. It has become clear in recent years that not all cells within the brain tumor have an equal potential to divide and drive tumor growth. As such, a fraction of tumor cells called brain tumor stem cells (BTSCs) are thought to be the primary origin of tumor re-growth after surgery, in addition to being resistant to standard treatments including chemotherapy and irradiation. Therefore, targeting BTSCs may be a way to effectively treat glioblastomas. In an effort to...